Related Experiment Video
Updated: Sep 20, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
TRIM29 upregulation contributes to chemoresistance in triple negative breast cancer via modulating S100P-β-catenin
Qitong Wu1, Sumit Siddharth2, Deepak Verma1
1Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB 1, Rm 145, Baltimore, MD, 21231, USA.
Abstract:
Triple negative breast cancer, an inherently aggressive disease, is further impaired by the limited therapeutic options and chemotherapy-resistance; hence, elucidating the signaling nodes underlying chemotherapy resistance is of major interest. Focusing on the differentially expressed genes in recurrent TNBC, we identified TRIM29, a ubiquitin ligase belonging to TRIM family, as a uniquely enriched protein in chemoresistant TNBC. Here, we demonstrate that chemoresistant TNBC cells are inherently aggressive, exhibiting elevated growth and migration potential compared to chemosensitive cells, and in particular, they possess higher TRIM29 expression whose expression level modulation results in altered chemosensitivity. TRIM29 overexpression reduces chemotherapy response whereas TRIM29 knockout not only increases chemosensitivity but also reduces TNBC tumor growth. Tumor-dissociated cells maintain TRIM29 knockout status as well as exhibit similar functional alterations as chemoresistant TNBC cells. Mechanistically, RNA-sequencing of parental-chemosensitive, chemoresistant-inherently overexpressing TRIM29 and chemoresistant-TRIM29 knockout TNBC cells reveals a unique set of genes (S100P, SERPINB3, SERPINB4, CEACAM5, CEACAM6 and CDH6) showing significant upregulation with the acquisition of chemoresistance and downregulation with the TRIM29 knockout. Furthermore, an enrichment of β-catenin pathway in chemoresistant TNBC cells is observed. We uncovered a functional network where S100P, a metastasis inducing secretory factor, bidirectionally interacts with TRIM29, and modulates the expression of SERPINB3, SERPINB4, CEACAM5, CEACAM6 as well as β-catenin pathway genes. Showing the functional importance, S100P inhibitor reduces the growth and mammosphere formation in chemoresistant TNBC. Moreover, combining β-catenin inhibitor with chemotherapy shows synergistic inhibition of chemoresistant TNBC cells. Indeed, higher expression of TRIM29, S100P and β-catenin associates with reduced recurrence free survival. This work proposes TRIM29 as an important node that modulates a unique gene network in chemoresistant TNBC and whose biological impact is mediated by modulation of S100P and β-catenin.
Insights
Triple negative breast cancer (TNBC) chemoresistance involves TRIM29, which promotes aggressive cell behavior and resistance. Targeting TRIM29, S100P, and β-catenin pathways offers new therapeutic strategies for TNBC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Triple negative breast cancer (TNBC) presents limited therapeutic options and significant chemotherapy resistance.
- Identifying key molecular drivers of chemoresistance is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of TRIM29 in TNBC chemoresistance.
- To elucidate the molecular mechanisms and signaling pathways involved in TRIM29-mediated chemoresistance.
Main Methods:
- Differential gene expression analysis in recurrent TNBC.
- TRIM29 expression modulation (overexpression and knockout) in TNBC cells.
- RNA-sequencing to identify downstream genes and pathways.
- Inhibitor studies targeting S100P and β-catenin pathways.
Main Results:
- TRIM29 is highly expressed in chemoresistant TNBC and its modulation affects chemosensitivity and tumor growth.
- TRIM29 knockout increases chemosensitivity and reduces TNBC tumor growth.
- TRIM29 regulates a network of genes including S100P, SERPINB3/4, CEACAM5/6, and CDH6, and influences the β-catenin pathway.
- S100P and β-catenin inhibition synergistically impacts chemoresistant TNBC growth and survival.
Conclusions:
- TRIM29 is a critical regulator of chemoresistance in TNBC, promoting aggressive phenotypes.
- The TRIM29-S100P-β-catenin axis represents a promising therapeutic target for overcoming TNBC chemoresistance.
Related Concept Videos
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

